)
Visual
test
Arovella Therapeutics
Arovella Therapeutics (ALA) investor relations material
Arovella Therapeutics H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary18 Feb, 2026
Executive summary
Loss from continuing operations increased 29% year-over-year to $1,878,707 for the half-year ended 31 December 2025.
Revenue and other income decreased 2% year-over-year to $3,624,499.
Cash at bank as of 31 December 2025 was $19,366,833, down from $20,877,185 at 30 June 2025.
IND-enabling activities for lead asset ALA-101 completed and IND filed with the U.S. FDA; post-period, IND accepted, enabling first-in-human clinical studies.
Advanced CLDN18.2-targeting CAR program, demonstrating strong activity against pancreatic cancer cells.
Financial highlights
Revenue and other income: $3,624,499, down 2% year-over-year.
Loss from continuing operations: $1,878,707, up 29% year-over-year.
Net tangible assets per share: 1.57 cents, down from 1.69 cents at 31 December 2024.
R&D tax incentive income recognized: $3,208,888.
No dividends paid or declared for the period.
Outlook and guidance
Company is fully funded to complete Phase 1 clinical trial for ALA-101.
Focus remains on advancing ALA-101 into clinical trials and expanding the CAR-iNKT platform for solid tumors.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Arovella Therapeutics
- IND filed for ALA-101, Phase 1 trial set for 2026, $19.4M cash, and robust pipeline expansion.ALA
Q2 2026 TU23 Jan 2026 - Clinical and strategic milestones achieved as CAR-iNKT pipeline advances toward trials.ALAAGM 202529 Dec 2025
- Strong cash position and clinical progress with ALA-101 and ALA-105 programs, plus new US patent.ALAQ1 2026 TU7 Dec 2025
- $23.5M cash and $15M raise secure phase I trial and pipeline progress for 2025 milestones.ALAQ3 202528 Nov 2025
- Two placement-related resolutions were voted on, with results to be released on ASX.ALAEGM 202527 Nov 2025
- Off-the-shelf iNKT cell therapies advance to clinical trials, targeting blood and solid cancers.ALAInvestor Presentation18 Nov 2025
- Off-the-shelf iNKT cell therapies advance toward clinical trials, targeting key cancer indications.ALAInvestor Presentation23 Sep 2025
- Loss narrowed and cash reserves strengthened as lead iNKT cell therapy advances to clinical trials.ALAH2 202531 Aug 2025
- $20.9M cash enables clinical trial progress and pipeline expansion, with 7.5 quarters funding secured.ALAQ4 2025 TU28 Jul 2025
Next Arovella Therapeutics earnings date
Q3 202616 Apr, 2026
Arovella Therapeutics
Next Arovella Therapeutics earnings date
Q3 202616 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage